Fig. 2
Chemotherapy receipt amongst (a) BRCA1 and (b) BRCA2/PALB2 carriers with T1N0 invasive breast cancer (n=89). ER+HER2- estrogen receptor positive, HER2-negative; HER2+ HER2-positive; TNBC Triple negative breast cancer
Fig. 2 | Hereditary Cancer in Clinical Practice